{"id":63918,"date":"2026-06-29T02:08:19","date_gmt":"2026-06-29T06:08:19","guid":{"rendered":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/ipsen-to-acquire-kartos-therapeutics-in-1-75-billion-deal-to-bolster-oncology-pipeline\/63918\/"},"modified":"2026-06-29T02:08:19","modified_gmt":"2026-06-29T06:08:19","slug":"ipsen-to-acquire-kartos-therapeutics-in-1-75-billion-deal-to-bolster-oncology-pipeline","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/ipsen-to-acquire-kartos-therapeutics-in-1-75-billion-deal-to-bolster-oncology-pipeline\/63918\/","title":{"rendered":"Ipsen to Acquire Kartos Therapeutics in $1.75 Billion Deal to Bolster Oncology Pipeline"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Ipsen (<a href=\"\/stock\/IPN\">IPN<\/a>)<\/strong> has entered a definitive agreement to acquire <strong>Kartos Therapeutics<\/strong> for an upfront payment of <strong>$450 million<\/strong>, with total potential deal value reaching <strong>$1.75 billion<\/strong> through milestone payments.<\/li>\n<li>The acquisition centers on <strong>navtemadlin<\/strong>, a Phase III oral MDM2 inhibitor targeting <strong>myelofibrosis<\/strong>, a rare and aggressive blood cancer.<\/li>\n<li>Shareholders of Kartos are eligible for up to <strong>$1.3 billion<\/strong> in additional regulatory and sales-based milestones.<\/li>\n<li>The transaction is expected to close by the <strong>end of Q3 2026<\/strong>, with Ipsen anticipating the deal to be accretive to core operating income starting in <strong>2029<\/strong>.<\/li>\n<\/ul>\n<p><strong>Ipsen (<a href=\"\/stock\/IPN\">IPN<\/a>)<\/strong>, the French biopharmaceutical giant, announced on Monday a significant expansion of its oncology portfolio through the acquisition of California-based <strong>Kartos Therapeutics<\/strong>. Under the terms of the merger, Ipsen will pay an initial <strong>$450 million<\/strong> in cash, with the total transaction value potentially climbing to <strong>$1.75 billion<\/strong> if specific regulatory and commercial milestones are met.<\/p>\n<p>The deal provides Ipsen with full rights to <strong>navtemadlin<\/strong>, a late-stage investigational therapy designed to treat patients with <strong>myelofibrosis<\/strong> who have shown a suboptimal response to the current standard of care, ruxolitinib. Navtemadlin works as an oral MDM2 inhibitor, aiming to restore the natural tumor-suppressing function of the <strong>p53 protein<\/strong>, which is frequently suppressed in various cancers.<\/p>\n<p><em>Market analysts view the move as a strategic effort by Ipsen to fill a critical gap in the hemato-oncology market.<\/em> Currently, patients who discontinue ruxolitinib treatment face a dismal prognosis, with median overall survival rates often limited to one or two years. Ipsen CEO <strong>David Loew<\/strong> stated that the acquisition reflects the company&#39;s focus on &quot;bringing transformational treatments to people living with cancer&quot; and could establish a new treatment paradigm as early as <strong>2028<\/strong>.<\/p>\n<p>Financially, Ipsen (<a href=\"\/stock\/IPN\">IPN<\/a>) noted that the acquisition will have <strong>limited dilution<\/strong> to its 2026 full-year financial guidance. The company expects the program to contribute positively to its core operating income by <strong>2029<\/strong>, following the anticipated completion of the ongoing <strong>Phase III POIESIS registrational trial<\/strong>, with top-line data expected in <strong>2027<\/strong>.<\/p>\n<p>The transaction remains subject to customary closing conditions, including the expiration of the waiting period under the <strong>Hart-Scott-Rodino Antitrust Improvements Act<\/strong>. This acquisition follows a string of recent deals by Ipsen, including the purchase of <strong>ImCheck Therapeutics<\/strong> in late 2025, as the firm continues to pivot toward high-growth specialty care and rare disease markets.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Ipsen (IPN) has entered a definitive agreement to acquire Kartos Therapeutics for an upfront payment of $450 million, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[8715,19795,19796,19797,19798,19799],"class_list":["post-63918","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-oncology","tag-ipsen","tag-kartos-therapeutics","tag-myelofibrosis","tag-ipn","tag-ipsey"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/63918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=63918"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/63918\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=63918"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=63918"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=63918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}